Related references
Note: Only part of the references are listed.Chronic inflammation, cardiometabolic diseases and effects of treatment: Psoriasis as a human model
Milena Aksentijevich et al.
TRENDS IN CARDIOVASCULAR MEDICINE (2020)
Activated Platelets Induce Endothelial Cell Inflammatory Response in Psoriasis via COX-1
Michael S. Garshick et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2020)
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
Donna K. Arnett et al.
CIRCULATION (2019)
Inflammasome Signaling and Impaired Vascular Health in Psoriasis
Michael S. Garshick et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2019)
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities
Craig A. Elmets et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)
Serum YKL-40 as a potential biomarker of inflammation in psoriasis
Anna Baran et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2018)
Reduction of Inflammatory and Cardiovascular Proteins in the Blood of Patients with Psoriasis: Differential Responses between Tofacitinib and Etanercept after 4 Weeks of Treatment
Jaehwan Kim et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2018)
Psoriasis and comorbid diseases Epidemiology
Junko Takeshita et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
GlycA, a novel biomarker of systemic inflammation and cardiovascular disease risk
Margery A. Connelly et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2017)
Association Between Skin and Aortic Vascular Inflammation in Patients With Psoriasis A Case-Cohort Study Using Positron Emission Tomography/Computed Tomography
Amit K. Dey et al.
JAMA CARDIOLOGY (2017)
GlycA Is a Novel Biomarker of Inflammation and Subclinical Cardiovascular Disease in Psoriasis
Aditya A. Joshi et al.
CIRCULATION RESEARCH (2016)
Utility of a novel inflammatory marker, GlycA, for assessment of rheumatoid arthritis disease activity and coronary atherosclerosis
Michelle J. Ormseth et al.
ARTHRITIS RESEARCH & THERAPY (2015)
Psoriasis and Major Adverse Cardiovascular Events: A Systematic Review and Meta-Analysis of Observational Studies
Ehrin J. Armstrong et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2013)
Inflammation in Atherosclerosis
Peter Libby
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2012)
Attributable Risk Estimate of Severe Psoriasis on Major Cardiovascular Events
Nehal N. Mehta et al.
AMERICAN JOURNAL OF MEDICINE (2011)
CCL20 Is Increased in Hypercholesterolemic Subjects and Is Upregulated By LDL in Vascular Smooth Muscle Cells Role of NF-κB
Olivier Calvayrac et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2011)
Genetic Deletion of Chemokine Receptor Ccr6 Decreases Atherogenesis in ApoE-Deficient Mice
Wuzhou Wan et al.
CIRCULATION RESEARCH (2011)
Vascular Inflammation in Obesity and Sleep Apnea
Sanja Jelic et al.
CIRCULATION (2010)
Association of Psoriasis With Coronary Artery, Cerebrovascular, and Peripheral Vascular Diseases and Mortality
Srjdan Prodanovich et al.
ARCHIVES OF DERMATOLOGY (2009)
Th17 Cytokines Stimulate CCL20 Expression in Keratinocytes In Vitro and In Vivo: Implications for Psoriasis Pathogenesis
Erin G. Harper et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2009)
Low Expression of the IL-23/Th17 Pathway in Atopic Dermatitis Compared to Psoriasis
Emma Guttman-Yassky et al.
JOURNAL OF IMMUNOLOGY (2008)
Endothelial function and dysfunction - Testing and clinical relevance
John E. Deanfield et al.
CIRCULATION (2007)
Risk of myocardial infarction in patients with psoriasis
Joel M. Gelfand et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Endothelial activation. Sliding door to atherosclerosis
G Desideri et al.
CURRENT PHARMACEUTICAL DESIGN (2005)
The CC chemokine CCL20 and its receptor CCR6
E Schutyser et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2003)
Inflammation and atherosclerosis
P Libby et al.
CIRCULATION (2002)
Share Paper
